Robert L. (Bob) Comis, M.D., passed away suddenly on May 10, 2017. The oncology community remembers with great affection his many contributions to our field. Dr. Comis was a medical oncologist who made major advances in the treatment of lung cancer, from the time he was the director of clinical research in that field in the extramural program of the National Cancer Institute (NCI) until his more recent involvement in facilitating the implementation of personalized medicine studies through international initiatives. As Group Co-Chair of ECOG-ACRIN and President of the Coalition of Cancer Cooperative Groups, Bob was a tireless advocate for a system that used public resources to address important research questions not answerable by other means. Dr. Comis knew better than anyone how to make the complex ecosystem of NCIfunded cancer clinical trials work for both researchers and patients. He succeeded because of his ability to inspire others with his important ideas, his straightforward approach, and his willingness to take on difficult challenges.
Bob attended Fordham University and received his M.D. from the State University of New York (SUNY) in Syracuse, New York. His commitment to clinical research in cancer preceded even his training as an oncologist, when he accepted an assignment to work at the NCI's Chemotherapy Unit in Kompala, Uganda, under the direction of Paul Carbone. There he had firsthand experience in providing remarkably effective chemotherapy for Burkitt lymphoma, an epidemic malignancy in children discovered a few years earlier by Dennis Burkitt. From 1972 to 1974, he was a staff associate at the National Cancer Institute's Cancer Therapy Evaluation Program and the NCI-Veteran's Administration Medical Oncology Branch. It was there that he saw the potential for marshalling the resources of the NCI's investigational drug branch to change cancer treatment through combined-modality clinical trials. 
